Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dewei She

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Rheumatology and Therapy|October 4, 2023
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled TrialCory Perugino, Emma L Culver, Arezou Khosroshahi, et al.
Journal of the American Heart Association|June 14, 2021
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol TransportRichard T George, Liron Abuhatzira, Susan M Stoughton, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 25, 2021
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b designMarc P Bonaca, Richard T George, David A Morrow, et al.
Annals of Clinical and Translational Neurology|October 7, 2023
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphismHo Jin Kim, Orhan Aktas, Kristina R Patterson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.
The Lancet. Neurology|May 17, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce A C Cree, Ho Jin Kim, Brian G Weinshenker, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentumBrian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.
Ebiomedicine|November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L Bennett, Orhan Aktas, William A Rees, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Rheumatology and Therapy|October 4, 2023
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled TrialCory Perugino, Emma L Culver, Arezou Khosroshahi, et al.
Journal of the American Heart Association|June 14, 2021
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol TransportRichard T George, Liron Abuhatzira, Susan M Stoughton, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 25, 2021
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b designMarc P Bonaca, Richard T George, David A Morrow, et al.
Annals of Clinical and Translational Neurology|October 7, 2023
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphismHo Jin Kim, Orhan Aktas, Kristina R Patterson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.
The Lancet. Neurology|May 17, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce A C Cree, Ho Jin Kim, Brian G Weinshenker, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentumBrian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.
Ebiomedicine|November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L Bennett, Orhan Aktas, William A Rees, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Pageof 4